ReviewIn vivo (Athens, Greece)
Pericardial Synovial Sarcoma: Case Report, Literature Review and Pooled Analysis.
Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Primary cardiac synovial sarcoma presenting with right heart failure and superior vena cava syndrome: a multimodal case report.International journal of surgery case reports · 2026Article
- Article
- Article
- Heart-breaking tumours: a case series of malignant pericardial effusion.European heart journal. Case reports · 2025Article
- Article
- Case report: Primary cardiac synovial sarcoma with suspected connective tissue disease diagnosed by EBUS-TBMB.Frontiers in medicine · 2025Article
- Synovial sarcoma of the ethmoid sinus with extension to the cavernous sinus: a case report and literature review.Journal of surgical case reports · 2024Article
- Pericardial synovial sarcoma in a young adult: case report of a rare malignancy.Ecancermedicalscience · 2024Article
- Case report: Characteristics and nature of primary cardiac synovial sarcoma.Frontiers in oncology · 2024Article
- Monophasic pericardial synovial sarcoma in a turkish female patient: a very rare case with cyto-histopathological findings.Journal of cardiothoracic surgery · 2023Article
- An Extremely Rare and Demanding Diagnosis of Primary Renal Synovial Sarcoma: A Case Report.Cureus · 2023Article
- A rare case of synovial sarcoma of diaphragm.Cancer reports (Hoboken, N.J.) · 2022Article
- Recurrent primary intracranial synovial sarcoma, a case report and review of the literature.Clinical case reports · 2022Article
- Primary Pericardial Synovial Sarcoma: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Case Report: A Young Man With Giant Pericardial Synovial Sarcoma.Frontiers in cardiovascular medicine · 2022Article
- A Clinico-Pathologic Approach to the Differential Diagnosis of Pericardial Tumors.Current cardiology reports · 2021Review
- Diagnostic approach to a cardiac mass: a case report of misdiagnosed cardiac synovial sarcoma.European heart journal. Case reports · 2021Article
- Importance of muldisciplinary management of giant mediastinal sarcoma: A case report with phrenic nerve reconstruction.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. CASE REPORT: We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. MATERIALS AND
methodsData from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months.
conclusionOnly complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.